DPT02 : A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18-120Age 18-120

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy,Treatment | Bowel (colorectum),Breast,Female reproductive organs,Lung,Stomach and upper gastrointestinal tract,Urinary systemBile duct,Bladder,Breast,Cervix,Colorectum,Endometrium,Epithelial,Lung,Non-Small Cell Lung Cancer,Ovary,Pancreas,Stomach

Trial Overview Read MoreRead more

This phase II trial aims to study the effectiveness of an anti-body drug in patients with selected HER2-expressing cancers.
 

This trial is treating patients with HER2 expressing cancers, including bladder cancer, billiary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and other rare cancer types.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Commercial Sponsor

AstraZeneca

Summary

This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. Eligible patients will be assigned to a treatment cohort based on their cancer type.

Recruiting Hospitals Read MoreRead more

Olivia Newton-John Cancer Wellness & Research Centre
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next